CAS No. |
114-07-8 |
中文名称 |
(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-(((2S,3R,4S,6R)-4-(二甲氨基)-3-羟基-6-甲基四氢-2H-吡喃-2-基)氧基)-14-乙基-7,12,13-三羟基-4-(((2R,4R,5S,6S)-5-羟基-4-甲氧基-4,6-二甲基四氢-2H-吡喃-2-基)氧基)-3,5,7,9,11,13-六甲基氧杂环十四烷-2,10-二酮 |
英文名称 |
(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-ethyl-7,12,13-trihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione |
别名 |
Derimer | Erycin | Skid Gel E | Ermycin | Erythrocin | Kesso-Mycin | erthromycin | Erythromycine | Pantoderm | Akne-Mycin | Ery-B | Sansac | Acnesol | E-Mycin (base) | Eryhexal | Iloticina | Endoeritrin | Erycinum | Mephamycin | Pantodrin | Abomacetin | A |
标准英文名 |
(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-ethyl-7,12,13-trihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione |
MDL No. |
MFCD00084654 |
分子式 |
C37H67NO13 |
分子量 |
733.46
|
精确分子量 |
733.46
|
SMILES |
C[C@@H]([C@@H]([C@H](C(O[C@@H]([C@@](O)([C@@H]([C@H](C([C@@H](C[C@]1(O)C)C)=O)C)O)C)CC)=O)C)O[C@H]2C[C@](C)([C@H]([C@@H](O2)C)O)OC)[C@H]1O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O |
标准SMILES |
CO[C@]1(C)C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@H]2C)O[C@@H](C)[C@@H]1O |
用途 |
Erythromycin is a macrolide antibiotic used for the treatment of infections caused by Gram-positive bacteria, particularly in patients allergic to penicillin or infected with penicillin-resistant strains such as Staphylococcus aureus; it is also effective against Streptococcus and Streptococcus pneumoniae infections, and is used in combination with diphtheria antitoxin for carriers of Corynebacterium diphtheriae; it serves as a first-line agent for Legionnaires' disease, Mycoplasma pneumonia, infant pneumonia and colitis caused by Chlamydia trachomatis, and skin and soft tissue infections; additionally, erythromycin exhibits prokinetic effects on the gastrointestinal tract, promoting esophageal contraction and increasing lower esophageal sphincter pressure (LESP), enhancing antral contractions and coordinating antral-duodenal motility, inducing migrating motor complex (MMC) phase III contractions, and stimulating colonic motility and gallbladder contraction, thereby effectively treating various gastrointestinal motility disorders. |
InChIKey |
ULGZDMOVFRHVEP-RWJQBGPGSA-N |